Objectives: The purpose of this study was to investigate effects of adipocytes on osteoclast adhesion-related molecules.
| INTRODUCTION
The prevalence of obesity or overweight continues to be unacceptably high and of public health concern worldwide. Clinical evidences indicate that obesity is a risk factor for osteoporosis in humans. 1 An inverse relationship between bone mass and marrow adiposity has been observed under pathological and physiological conditions.
2-4
Adipocytes are present in bone marrow niche and are shown to increase greatly with advanced age, obesity and associated abnormal bone metabolism, such as osteoporosis, rheumatoid arthritis and metastatic cancers. 5 Therefore, bone marrow adipogenesis has been recently regarded as a therapeutic target for prevention of bone loss. In vitro studies demonstrated that co-culture of osteoclast precursors with adipocytes or addition of the culture supernatant from bone marrow adipocyte to RAW264.7 cells under low-dose of RANKL could promote osteoclastogenesis and increase the area of bone resorption, 6 indicating that adipocytes could enhance osteoclast differentiation and resorption ability through secretion of pro-osteoclastogenic cytokines. Up to now, several proinflammatory cytokines and adipocyte-specific factors such as leptin and adiponectin have been shown to contribute to the adipocytic regulation of osteoclast formation. 7 Cell Proliferation. 2017;50:e12317. wileyonlinelibrary.com/journal/cpr
Chemokines have recently been demonstrated to play essential roles in osteoclast differentiation. CXCL12, a member of CXC chemokine family constitutively expressed by murine and human bone marrow stromal cells, has been implicated in mediation of survival for progenitor cells and regulation of their homing, retention, fusion and function. [8] [9] [10] [11] Recently, CXCL12 is also shown to be expressed by adipocyte and functions by binding to its major receptor CXCR4, a G-proteincoupled receptor which is expressed on many cell types, including osteoclast precursors. [12] [13] [14] De Klerck et al. 15 reported that CXCL12
potentiates receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation and activity from splenocytes, which can be counteracted by AMD3100, a specific antagonist for CXCR4. Thus, CXCL12/CXCR4 signalling pathway appears to be closely involved in the process of osteoclast differentiation.
NFAT2, a master transcription factor of osteoclastogenesis, binds to its own gene promoter accelerating its own transcription and further induces the expression of key genes associated with osteoclast activation. 16 Active mature osteoclasts are typically multinuclear giant cells that have strong potency to degrade bone matrix. The achievement of bone resorption by osteoclasts requires the tight attachment to bone surfaces and the formation of ruffled border, where they degrade the mineralized bone matrix by releasing several proteolytic enzymes such as matrix metalloproteinase-9 (MMP-9) and cathepsin K. 17 The process of attachment of osteoclasts to mineral surface requires a series of osteoclast-derived adhesion molecules including CD44 and integrin β3 sharing a common ligand, osteopontin (OPN), which is also expressed and secreted by osteoclasts. 18, 19 The activation of CXCL12/ CXCR4 has been noted as one of the key regulatory mechanisms of multiple intracellular changes, such as actin cytoskeletal reorganization and adhesion molecules expression. 20 However, much less has been known about the role of CXCL12/CXCR4 in osteoclastic adhesion so far. The objective of this study was to investigate the effect of adipocyte on the expression of osteoclast adhesion-related molecules and the role of CXCL12 in the process. 
| MATERIALS AND METHODS

| Materials
| ELISA assay for CXCL12 in ADIPO CM
The concentrations of CXCL12 in serum-free culture medium conditioned by ST2-adipocytes as mentioned above were detected. Culture medium of serum-free α-MEM was used as control. The samples were assayed using commercially available enzyme-linked immunosorbent assay (ELISA) kit and the data were expressed as pg/mL. Experiments were repeated at least three times each time in triplicate.
Cell viability was expressed as a percentage of the control.
| Preparation of bone marrow-derived macrophages (BMMs)
BMMs were isolated from whole bone marrow of 4-to 6-week old C57BL/6 male mice. Briefly, after killing the mice, total bone marrow 
| Resorption pit assay
RAW264.7 cells or BMMs were seeded in Corning Osteo Assay Surface 96-well plates coated with calcium phosphate substrate at a density of 5 × 10 3 cells/well and allowed to attach overnight. The cells were incubated at 37°C in 5% CO 2 for 7 days, and the medium was changed every 48 hours. After 7 days, cells were washed with a 10% bleach solution.
Images of resorption pits on the plates were captured using a light microscope (CKX41; Olympus) and quantified using Image-Pro Plus 6 software, and the results were expressed as a percentage of the total field area. 
| Quantitative real-time PCR analysis
Total RNA was extracted from RAW264. Table 1 . Data were normalized against the levels of glyceraldehyde-3 phosphate dehydrogenase (GAPDH) DNA and were compared with normalized control values.
| Western blot assay
Cells were lysed and centrifuged and the protein content was quantified by BCA protein assay kit (Pierce, Rockford, USA). Western blot analyses were then performed using NuPAGE 4-12% Bis-Tris gradient gels and 0.45 μm 
| Statistical analyses
All data analyses were performed using spss 14.0 software. Data were presented as the mean ± standard deviation. Statistical comparisons were assessed by the unpaired t test between two groups and by the one-way analysis of variance among more than two groups. P<.05 was considered statistically significant. in the α-MEM, P<.01, Figure 1C) . To explore the effect of CXCL12 on the proliferation viability of osteoclast precursor cells, CCK-8 assay was performed using RAW264.7 cells ( Figure 1D ) and BMMs ( Figure 1E ).
| RESULTS
| CXCL12 was abundantly detected in adipocyte-
We found that CXCL12 had no effect on proliferation viability of osteoclast precursor cells at the concentrations used in this study.
| ADIPO CM enhanced osteoclast formation and resorption ability
To investigate the direct role of ADIPO CM on osteoclast differentiation and resorption ability, we examined the effect of ADIPO CM on osteoclast differentiation and pit formation from murine RAW 264.7 cells (Figure 2A ) and BMMs ( Figure 2B ). RAW264.7 cells were cul- Figure 2D ).
Besides, the proportion of resorption area is also statistically enhanced after treatment for RAW264.7 cells with ADIPO CM (2.67 ± 0.11% in the control group vs 6.69 ± 0.11% in the ADIPO CM group, P<.01).
Similarly, after induction of BMMs, the group of ADIPO CM showed statistically greater resorption area than control (0.98 ± 0.09% in the control group vs 6.08 ± 0.12% in the ADIPO CM group, P<.01, Figure 2E ). These results are accordant with data from RAW264.7 cells and the model of BMMs confirming the enhanced effect of ADIPO CM on osteoclast differentiation and resorption ability.
| Adipocyte-derived CXCL-12 enhanced osteoclast differentiation and resorption ability in RAW264.7 cells
To understand the effects of adipocyte-derived CXCL12 on osteoclast differentiation and resorption ability, we incubated RANKL-treated RAW264.7 cells in the absence or presence of recombinant CXCL12 Figure 3C , it was revealed that the numbers of osteoclasts were significantly increased in the presence of CXCL12 as compared with ADIPO CM only, while addition of AMD3100 lessened this effect. However, although treatment with ADIPO CM and AMD3100 showed more osteoclasts than group of control, there was no obvious distinction between them.
In addition, the pit-forming assay showed that treatment with ADIPO CM clearly enhanced the surface of calcium phosphate resorbed in comparison to control. Statistical analysis revealed that CXCL12 treatment induced an increase in the proportion of resorption area, while after blocking the CXCL12/CXCR4 signalling pathway using AMD3100, the area of bone resorption pits were reduced significantly (3.51 ± 0.21% in the control group vs 8.32 ± 0.21% in the ADIPO CM group, vs 9.26 ± 0.18% in the ADIPO CM + CXCL12 group vs 5.19 ± 0.15% in the ADIPO CM + AMD3100 group, P<.05, Figure 3D ). Western blot analysis statistically showed that the level of NFAT2, a master transcription factor, was increased by ADIPO CM, while AMD3100 inhibited this effect. Cathepsin K and MMP-9 have been convincingly recognized as the most potent proteolytic effectors of osteoclast-mediated bone resorption. Transcription of cathepsin K and MMP-9, two bone remodelling genes, were increased in the presence of ADIPO CM, while this effect was disturbed with AMD3100 treatment ( Figure 4A ). Similarly, protein expression of cathepsin K and MMP-9 in the culture of ADIPO CM were enhanced with treatment of CXCL12 while partially abolished by AMD3100 ( Figure 4B ). Besides, statistical analysis revealed that csrc, as a key factor for the formation of ruffled border, had analogical expression levels of gene in osteoclasts and protein (Figure 4 ).
| Adipocyte-derived CXCL-12 upregulated osteoclast adhesion-related molecules expression
To further explore the role of adipocyte-derived CXCL12 in the expression of osteoclast-related adhesion molecules, we analysed the mRNA and protein expression of osteoclast adhesion-related molecules such as CD44, β3 integrin and OPN in all groups ( Figure 5 ).
qRT-PCR results statistically showed that the expression of CD44, β3 integrin and OPN mRNA was enhanced in the presence of ADIPO 
| DISCUSSION
Recent studies have shown that body fat mass is negatively correlated with bone mass when the mechanical loading effect of body weight is statistically removed. Therefore, obesity has been identified as a risk factor for osteoporosis. 22, 23 In this study, we aimed to examine the contribution of adipocyte-derived factors to osteoclast differentiation and adhesionrelated molecules in vitro, focusing on the involvement of CXCL12/ CXCR4 signalling pathway in osteoclast differentiation and function. The results showed that adipocyte promoted osteoclast differentiation, function and expression of adhesion-related molecules via secreting CXCL12.
Thus, targeting CXCL12/CXCR4 signalling pathway may present a promising therapeutic approach for osteoporosis in obese people.
Several studies have reported a positive relationship of the marrow medullary adipogenesis and osteoclastgenisis. [24] [25] [26] In vivo, high-fat diet caused 2-fold to 3-fold in osteoclast formation and bone resorptive capacity compared with low-fat diet group. 27 In vitro, co-culture of osteoclast precursors with bone marrow-derived mesenchymal stem cell-derived adipocytes significantly enhanced osteoclast differentiation with low-dose RANKL. 6 Consistent with these studies, our results
showed that adipocyte supernatant effectively enhanced osteoclast differentiation and activity, implying that adipocyte promoted osteoclastogenesis in a paracrine manner. Recent studies suggested that adipocytes might modulate osteoclast differentiation and activity through secreting the factors, such as leptin, adiponectin and pro-inflammatory cytokines. 6, 7, 26, 28, 29 Whether adipocyte can supply additional factor to support and enhance osteoclastogenesis is not well understood.
CXCL12, a chemotactic factor, has been suggested to play potential roles in preosteoclast homing, retention, fusion and function by binding to its major receptor CXCR4. [8] [9] [10] Recently, adipocytes have been found to highly express CXCL12 both in vitro and in vivo, a fact proposed CXCL12 as a potential bridging factor linking lipid metabolism and osteoclastic bone resorption. 30 In this study, ELISA analyses revealed that CXCL12 was highly upregulated in adipocyte supernatant. We also showed that media conditioned by adipocytes significantly accelerated osteoclast differentiation, a process that can be further augmented by simultaneously treating with recombinant CXCL12 ligands. Notably, treatment with AMD3100 revealed an effect of inhibition on adipocyteinduced osteoclast differentiation and resorptive ability. Thus, our results suggested that adipocyte enhanced osteoclast differentiation and activity partially through CXCL12/CXCR4 signalling pathway.
It is reported that NFATc1 plays pivotal role in osteoclast formation, mature and activation via upregulation of various genes responsible for osteoclast fusion, adhesion, migration and bone resorption. 16, 31 In this study, western blot revealed that treatment with AMD3100
could inhibit the positive role of ADIPO CM in the expression of NFAT2 suggesting that CXCL12-derived adipocyte contributed to osteoclast development. The initial event in bone resorption is the formation of the ruffled border and osteoclast adhesion to the target matrix. Osteoclasts synthesize several critical adhesion-related molecules such as β3 integrin and CD44, through which osteoclasts bond to bone matrix and initiate the following resorption. β3 integrin and CD44 may regulate osteoclastic adhesion and migration by interacting with secreted matrix elements such as OPN. 32 It has been reported that OPN promoted osteoclastic migration in the metastatic lesion by its high affinity to CD44 and β3 integrin on osteoclast membrane, which leaded to immediate osteolysis. 33, 34 In our study, supernatant of ST2-adipocyte culture enhanced the expression of osteoclastic adhesion molecules. Thus, it appears that some endogenous factors synthesized and secreted by adipocyte may be responsible for this effect. upon CXCL12 treatment, has been observed on lung cancer cells, pancreatic cancer cells and other cell types. 36, 37 Moreover, phosphorylation src at Tyr416 (p-src) appears to play an essential role in the dynamics and organization of actin cytoskeleton, as well as the socalled ruffled border. 38, 39 Deletion of c-src leads to reduced motility and alteration of the cytoskeleton in osteoclast, resulting ultimately in their lack of bone resorbing activity. 40 In our study, the fact that the expression of p-src in osteoclast was increased in the group of ADIPO CM and ADIPO CM + CXCL12, while inhibited in the group of ADIPO CM + AMD3100 revealed the important role of CXCL12 derived from adipocyte. However, osteoclast adhesion is a complex process mediated by several classes of cell adhesion molecules, and it is still not clear enough to explain the mechanism in detail. Thus, further research for effects of CXCL12 derived from adipocytes on osteoclast adhesion is required.
In conclusion, our study indicated the positive effects of adipocytes on osteoclast differentiation and expression of adhesion-related molecules, which were achieved partially through CXCL12/CXCR4
signalling pathway ( Figure 6 ).
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F I G U R E 5 CXCL12 derived from adipocyte upregulated the expression of osteoclast adhesion-related molecules. RAW264.7 cells were cultured for 4 days with control conditions, with ADIPO CM or with ADIPO CM in the presence of recombinant CXCL12 or AMD3100.
Quantitative RT-PCR analysis of osteoclast adhesion-related genes: β3 integrin, CD44 and OPN in osteoclasts were performed and data are graphed as fold change relative to control (A). Western blot of above molecules in osteoclasts was performed, and band intensity analysis of respective protein levels in osteoclasts was normalized to β-actin and represented as % control (B). Values are mean ± SD of three independent experiments. Means with different letters differ significantly from each other P<.05 F I G U R E 6 Schematic model for ADIPO CM regulation on the osteoclast differentiation and activation. Adipocytes secrete CXCL12 into extracellular environment. Then, the extracellular CXCL12 binds to its receptor CXCR4 expressed on the preosteoclasts, further to enhance the differentiation, and activity of osteoclasts as well as the expression of osteoclast adhesion-related molecules such as β3 integrin, CD44 and OPN
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